@BillAckman@PershingSquare@DavidOReillyHH
Re: $HHH pricing like an insurance company under the clouds of Eisman and Gober discussion. https://t.co/y2biZke8xL
Bill - I recommend reading a transcript of this discussion between Steve Eisman and a veteran former insurance examiner/forensic accountant. They discuss the life insurance industry’s “black hole of transparency” and a relatively unsophisticated states-level regulatory apparatus that is ill-equipped to examine what has become an over-levered space now largely controlled by private equity.
The overarching concern is private equity-backed insurance/reinsurance are masking extreme leverage through offshore Bermuda captives and illiquid affiliated credit. "Slow boiling frogs", Eisman says.
$HHH could benefit from some transparent messaging re: Vantage.
@BarkInvesting I see no difference - and he's still saying "we'll give it our best shot." Still hedging. Doesn't matter though - I think Neutron will fly, just maybe not this year. RKLB have demonstrated themselves to be stone cold assassins at executing across all fronts.
Dude, take a long view and just own HHH. Buy it for your kids. It may languish for a while, but it may not b/c markets are vulnerable and the Pershing Square team now owns the balance sheet - at a $100 print to cement control. Long term, it’s surely one of the best $4bn mkt cap bets you can make - not for a trade, but to own. #tradeElsewhereOwnHHH
@NotTheirScript@BillAckman@Harvard Agreed. Look at Austin University (soon to be f/k/a University of Austin TX). They’re doing exactly what a ground-up process should embody. Thank you, #BillAckman, for your generous contribution to the endowment and the solid branding advice.
https://t.co/qxMPBOTWCC
#RobertReich, go write a paper about it with #ClaudineGay and circulate it among some of the big HBS alumni and donors, including #JamieDimon, #MichaelBloomberg, #BillAckman, #RobertKtaft, #SherylSandberg, #StephenSchwarzman.
You folks, you’re not responsible for your own success!!
Make sure to cite #MichaelDell and me, #JayStout, as your inspiration.
While your’re at it, ask #ElizabethWarren why she wrote a friend of the court brief (Amicus Brief) in 2006 for a bunch of hedge fund lenders to bankrupt NextWave Telecom before its arguments to the Supreme Court. Her compensation reportedly was $119,000 - BUT, had she bought $0.50 stock in bankrupt NextWave before the Court’s 8-1 decision, she could have sold it for >$7…
#LawrenceTribe represented the estate and, well… I think his post-arguments trade panned out well, following even the perception of how our arguments went before all but Souter the lone dissent.
Point here is, #RobertReich, a generous mulligan for you. Go and start over. Then come talk to me.
#JayStout
@amitisinvesting Re: 2x’er… from the low-mid 20s, #RKLB provided Neutron remains on schedule and is successful. It was just stupid cheap a year ago, particularly for such a large moat business.
@humacyte 2/3 IF, big if, the BVP becomes the standard of care for a large segment of diabetics, the traditional dialysis business model is at risk. Maybe that’s why Fresenius (~$12bn mkt cap), has $175M invested in HUMA. Just sayin’…
@humacyte 1/3 - Smooth path to commercialization of ATEV for vascular trauma (starting post 8/10 PDUFA), then AV access in dialysis and for PAD (both late Phase 3 clinical trials). That’s a good business.
Today we announced the strengthening of our Board of Directors with two impactful leaders, Dr. John P. Bamforth and Dr. Keith Anthony (Tony) Jones. They have abundant experience in commercialization and health systems to guide us as we approach the anticipated launch of our investigational ATEV™ for vascular trauma repair.
Read more about their impressive backgrounds and our upcoming plans here: https://t.co/alJT4vscG4
#Humacyte #HealthcareInnovation #BoardOfDirectors #ATEV #Biotech